Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Serum VEGF levels
研究概览
简要总结
Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors
详细描述
Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Number of follicles greater than 12 mm after ovarian stimulation
- •Number of retrieved oocytes greater than 21
排除标准
- •>35 years-old
- •Endometriosis
- •Systemic pathology
- •Positive serologies for HBV, HBC and HIV
- •Abnormal karyotype
研究组 & 干预措施
Resveratrol
Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
干预措施: Resveratrol (Drug)
Resveratrol
Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
干预措施: Placebo (Drug)
Control
Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
干预措施: Resveratrol (Drug)
Control
Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
干预措施: Placebo (Drug)
结局指标
主要结局
Serum VEGF levels
时间窗: 1 day
Serum determination of VEGF levels
次要结局
- Hemoconcentration(1 day)
- Ascitis(1 day)
- Serum estradiol levels(1 day)
研究者
Juan A Garcia-Velasco
MD
IVI Madrid